Princeton Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.52M | Buy |
6,979
+28
| +0.4% | +$6.21K | 0.41% | 41 |
|
|
2025
Q4 | $1.59M | Sell |
6,951
-216
| -3% | -$49.2K | 0.41% | 37 |
|
|
2025
Q3 | $1.66M | Hold |
7,167
| – | – | 0.45% | 35 |
|
|
2025
Q2 | $1.33M | Sell |
7,167
-934
| -12% | -$174K | 0.4% | 40 |
|
|
2025
Q1 | $1.7M | Hold |
8,101
| – | – | 0.6% | 28 |
|
|
2024
Q4 | $1.44M | Sell |
8,101
-826
| -9% | -$152K | 0.45% | 38 |
|
|
2024
Q3 | $1.76M | Sell |
8,927
-1,170
| -12% | -$218K | 0.56% | 34 |
|
|
2024
Q2 | $1.73M | Sell |
10,097
-95
| -0.9% | -$15.7K | 0.56% | 33 |
|
|
2024
Q1 | $1.86M | Sell |
10,192
-75
| -0.7% | -$12.9K | 0.67% | 34 |
|
|
2023
Q4 | $1.59M | Sell |
10,267
-22,626
| -69% | -$3.3M | 0.64% | 36 |
|
|
2023
Q3 | $4.9M | Sell |
32,893
-6,339
| -16% | -$931K | 2.26% | 10 |
|
|
2023
Q2 | $5.29M | Sell |
39,232
-59
| -0.2% | -$8.65K | 2.19% | 10 |
|
|
2023
Q1 | $6.26M | Sell |
39,291
-5,443
| -12% | -$832K | 2.68% | 8 |
|
|
2022
Q4 | $7.23M | Sell |
44,734
-4,919
| -10% | -$754K | 3.21% | 6 |
|
|
2022
Q3 | $6.66M | Sell |
49,653
-92
| -0.2% | -$13.2K | 2.92% | 7 |
|
|
2022
Q2 | $7.62M | Buy |
49,745
+828
| +2% | +$127K | 2.95% | 8 |
|
|
2022
Q1 | $7.93M | Sell |
48,917
-562
| -1% | -$81.6K | 2.46% | 9 |
|
|
2021
Q4 | $6.7M | Buy |
49,479
+59
| +0.1% | +$6.97K | 1.92% | 15 |
|
|
2021
Q3 | $5.33M | Buy |
49,420
+176
| +0.4% | +$20.1K | 1.7% | 17 |
|
|
2021
Q2 | $5.55M | Buy |
49,244
+61
| +0.1% | +$6.87K | 1.72% | 18 |
|
|
2021
Q1 | $5.32M | Buy |
49,183
+192
| +0.4% | +$20.5K | 1.8% | 18 |
|
|
2020
Q4 | $5.25M | Buy |
48,991
+1,649
| +3% | +$158K | 1.88% | 18 |
|
|
2020
Q3 | $4.15M | Buy |
47,342
+1,204
| +3% | +$113K | 1.67% | 20 |
|
|
2020
Q2 | $4.53M | Buy |
46,138
+1,832
| +4% | +$161K | 2.01% | 18 |
|
|
2020
Q1 | $3.79M | Buy |
44,306
+2,385
| +6% | +$203K | 1.97% | 17 |
|
|
2019
Q4 | $3.87M | Buy |
41,921
+167
| +0.4% | +$13.9K | 1.73% | 21 |
|
|
2019
Q3 | $3.16M | Sell |
41,754
-1,680
| -4% | -$115K | 1.54% | 21 |
|
|
2019
Q2 | $3.16M | Sell |
43,434
-1,030
| -2% | -$81K | 1.54% | 23 |
|
|
2019
Q1 | $3.58M | Buy |
44,464
+12,085
| +37% | +$989K | 1.81% | 19 |
|
|
2018
Q4 | $2.98M | Sell |
32,379
-11,191
| -26% | -$984K | 1.74% | 22 |
|
|
2018
Q3 | $4.12M | Buy |
43,570
+17,472
| +67% | +$1.66M | 1.71% | 22 |
|
|
2018
Q2 | $2.42M | Buy |
26,098
+965
| +4% | +$94.2K | 1.05% | 28 |
|
|
2018
Q1 | $2.38M | Sell |
25,133
-1,352
| -5% | -$149K | 1.06% | 30 |
|
|
2017
Q4 | $2.56M | Buy |
+26,485
| New | +$2.5M | 1.14% | 29 |
|
Other funds holding ABBV
VCM
VPM
Princeton Capital Management's ABBV Position: Q1 2026 in Review
Princeton Capital Management increased its AbbVie (ABBV) stake by 0.4% in Q1 2026, buying an estimated $6.21K and bringing the position to 6,979 shares worth $1.52M. The position accounts for 0.41% of the portfolio, ranked #41.
Princeton Capital Management first reported a position in ABBV in Q4 2017 and has held it in 34 quarters since. The position peaked at $7.93M in Q1 2022. 4,079 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Princeton Capital Management held 6,979 shares of AbbVie worth $1.52M as of Q1 2026.
- Princeton Capital Management bought 28 AbbVie shares in Q1 2026, an estimated $6.21K.
- AbbVie made up 0.41% of Princeton Capital Management's portfolio in Q1 2026, its #41 holding.
- Princeton Capital Management first reported a position in AbbVie in Q4 2017 and has held it in 34 quarters since.
- Princeton Capital Management's AbbVie position peaked at $7.93M in Q1 2022.
- 4,079 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Princeton Capital Management's 13F filing for Q1 2026, filed 8 May 2026.